NEW YORK--(BUSINESS WIRE)--Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ solutions as prescription medical treatments, today unveiled a new brand identity, website, and logo ...
The study marks Click’s second active randomized clinical trial testing digital interventions in migraine patients. The ReMMiD-C trial will evaluate the efficacy and safety of investigational digital ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback